326 completed, 122 terminated, 93 recruiting, 90 active not recruiting. 353 Phase 2, 260 Phase 1, 77 Phase 3, 37 Not applicable, 6 Phase 4.
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| RPM Signals in Outpatient CAR T Therapy Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome | Not yet recruiting | Current Health | 125 | 2026-12-01 | 2026-10-20 | |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-05 | 2026-11-02 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-10-22 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 45 | 2026-09-01 | 2026-08-05 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
Showing 20 of 750. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (750) · Lymphoma, Non-Hodgkin (157) · Leukemia (105) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (104) · Leukemia, Myeloid, Acute (92) · Lymphoma, Mantle-Cell (87) · Multiple Myeloma (83) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (72) · Lymphoma, Follicular (71) · Myelodysplastic Syndromes (70) · Hodgkin Disease (68) · Lymphoma (68) · Lymphoma, Large B-Cell, Diffuse (67) · Lymphoma, B-Cell, Marginal Zone (54) · Neoplasms (48)
Chronic Disease (750) · Disease Attributes (750) · Hemic and Lymphatic Diseases (750) · Pathologic Processes (750) · Pathological Conditions, Signs and Symptoms (750) · Lymphatic Diseases (747) · Neoplasms by Histologic Type (747) · Immunoproliferative Disorders (746) · Immune System Diseases (743) · Lymphoproliferative Disorders (743) · Leukemia, Lymphoid (739) · Hematologic Diseases (736) · Leukemia, B-Cell (735) · Neoplasms (702) · Leukemia (645)
Rituximab (110) · Cyclophosphamide (82) · fludarabine (76) · venetoclax (68) · ibrutinib (63) · obinutuzumab (61) · fludarabine phosphate (56) · Bendamustine Hydrochloride (52) · Lenalidomide (42) · acalabrutinib (40) · Mycophenolic Acid (32) · Whole-Body Irradiation (27) · ofatumumab (24) · Tacrolimus (23) · zanubrutinib (23)
M.D. Anderson Cancer Center (49) · German CLL Study Group (22) · National Cancer Institute (NCI) (21) · Gilead Sciences (19) · AbbVie (17) · Gruppo Italiano Malattie EMatologiche dell'Adulto (15) · TG Therapeutics, Inc. (15) · City of Hope Medical Center (14) · Dana-Farber Cancer Institute (14) · AstraZeneca (13) · Fred Hutchinson Cancer Center (12) · Acerta Pharma BV (10) · Masonic Cancer Center, University of Minnesota (9) · National Heart, Lung, and Blood Institute (NHLBI) (9) · BeOne Medicines (8)
United States (516) · Italy (85) · France (81) · Germany (74) · United Kingdom (73) · Australia (64) · Spain (64) · Canada (56) · Poland (56) · China (54) · Belgium (44) · Israel (39) · Austria (34) · Czechia (34) · South Korea (33)
Michael Hallek, MD (8) · Alessandra Ferrajoli, MD (7) · Michael Choi, MD (5) · Januario Castro, M.D. (4) · Kerry A Rogers, MD (4) · Nicholas Chiorazzi, MD (4)
PMID 34398557, PMID 29358183, PMID 31023700, PMID 32499241, PMID 34515338, PMID 34608724, PMID 34865212, PMID 38620092, PMID 39563886, PMID 40266025, PMID 40396505, PMID 20882050, PMID 23065508, PMID 23524640, PMID 24782509, PMID 27601462, PMID 28751558, PMID 29296805, PMID 29880603, PMID 31196847, PMID 31208944, PMID 31723767, PMID 32599655, PMID 35014928, PMID 35377947, PMID 35829925, PMID 36617990, PMID 38502198, PMID 38598745, PMID 41363770, PMID 41749915, PMID 1009120, PMID 10204198, PMID 1068773, PMID 10771143, PMID 1131339, PMID 11333192, PMID 11703167, PMID 1250252, PMID 14965792, PMID 15092991, PMID 15689032, PMID 15711642, PMID 15911237, PMID 16186597, PMID 16219797, PMID 1719661, PMID 17389338, PMID 18003886, PMID 18039954
P30CA033572 (10), 2015 (9), P30CA015704 (9), 2023 (8), 2025 (7), 2014 (6), 2016 (6), P30CA016672 (5), 2005 (4), 2018 (4), P01CA018029 (4), P30CA016058 (4), 2009 (3), 2019 (3), U01CA076576 (3)